A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or Placebo Monotherapy in High-Risk Subjects with Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)

GlaxoSmithKline Research & Development Limited0 个研究点目标入组 680 人2007年1月17日

概览

暂无简介。

注册库

who.int

开始日期

2007年1月17日

结束日期

待定

最后更新

12年前

研究类型

Interventional clinical trial of medicinal product

性别

All

发起方

•1\. Willing and able to sign a written informed consent.
•2\. Histologically confirmed diagnosis of SCCHN of one of the following sites: oral cavity, oropharynx, hypopharynx and larynx.
•3\. Pathological Stage II, III or IVa with no evidence of gross residual diease, and at least one of the high risk factors by pathology (as listed in protocol)
•4\. Primary surgery with a curative intent completed within 4\-6 weeks (and no later than 7 weeks) prior to randomization. Subjects with a second primary tumour that has been resected at the same time as the original tumour wil be permitted according to this criterial listed in the protocol.
•5\. Complete recovery from the surgical procedure. Radiation therapy is required to start as soon as adequate healing has occurred. This is normally around 4\-6 weeks but no later than 8 weeks after surgery.
•6\. Adequate tumour specimen from archived or resected tissue must be available.
•7\. Male or female, between 18 and 70 years of age.
•Criteria for female subjects or female partners of male subjects as defined in the protocol
•8\. ECOG performance status 0, 1 or 2
•9\. Adequate haematology, renal and hepatic function , as defined in the protocol

•1\. Nasopharyngeal, paranasal sinuses or nasal cavity tumours
•2\. Head and neck cancer with histology other than squamous cell.
•3\. Evidence of distant metastases or gross post\-operative residual disease.
•4\. Evidence of second primary tumour that was not resected or exhibits gross post\-operative residual disease.
•5\. Any prior or current anticancer treatment of any kind – except the primary surgical resection. This will include but not exclusive to: prior tyrosine kinase inhibitors, prior neoadjuvant therapy, prior radiotherapy or use of any investigational agent.
•6\. Concurrent treatment with an investigational agent or participation in another clinical trial.
•7\. Concurrent use of CYP3A4 inducers or inhibitors while on investigational product. A standard 3\-day course of dexamethasone for the prevention of cisplatin induced nausea and vomiting is permitted.
•8\. Subjects with known history of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure;
•9\. Pregnant or lactating females
•10\. History of another malignancy within the last 5 years, with the exception of completely resected basal or squamous cell skin cancer, or successfully treated in\-situ carcinoma. History of non\-invasive lesion or in\-situ carcinoma, including in the head and neck region that was successfully treated with surgery, photodynamics or laser, will be permitted;